Non-Viral Gene Delivery Technologies Market Size to Hit USD 9.57 Billion by 2033, Growing at a CAGR of 12.55% - SNS Insider [Yahoo! Finance]
Arrowhead Pharmaceuticals, Inc. (ARWR)
Last arrowhead pharmaceuticals, inc. earnings: 2/5 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.arrowheadpharma.com/investor-relations
Company Research
Source: Yahoo! Finance
Austin, Texas, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Non-Viral Gene Delivery Technologies Market Size & Growth Analysis: According to SNS Insider estimates, the Non-Viral Gene Delivery Technologies Market size was valued at USD 3.73 billion in 2025 (Estimated) and is expected to reach USD 9.57 billion by 2033, growing at a CAGR of 12.55% over the forecast period of 2026–2033. The increasing focus on gene editing, RNA-based therapies, and personalized medicine is significantly contributing to market expansion. The Non-viral gene delivery systems such as lipid nanoparticles, polymer-based carriers, electroporation, and physical delivery methods are gaining traction due to their improved safety profiles, lower immunogenicity, scalable manufacturing, and flexibility in payload design compared to viral vectors. Get a Sample Report of Non-Viral Gene Delivery Technologies Market: https://www.snsinsider.com/sample-request/8166 These technologies are increasingly utilized in applications
Show less
Read more
Impact Snapshot
Event Time:
ARWR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARWR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARWR alerts
High impacting Arrowhead Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ARWR
News
- Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target raised by analysts at Piper Sandler from $70.00 to $100.00. They now have an "overweight" rating on the stock.MarketBeat
- Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)Business Wire
- Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target raised by analysts at Royal Bank Of Canada from $52.00 to $80.00. They now have an "outperform" rating on the stock.MarketBeat
- Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target raised by analysts at Bank of America Corporation from $62.00 to $81.00. They now have a "buy" rating on the stock.MarketBeat
- Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other TauopathiesBusiness Wire
ARWR
Earnings
- 11/25/25 - Miss
ARWR
Sec Filings
- 12/19/25 - Form 144
- 12/19/25 - Form 144
- 12/19/25 - Form 144
- ARWR's page on the SEC website